Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Anat ; 218(5): 510-6, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21355867

RESUMO

Although age-related changes in cancellous bone structure in human are relatively well characterized, few studies have addressed changes in cortical bone. We have investigated age-related changes in iliac crest bone biopsy specimens from 54 normal subjects, 23 men and 31 women, aged 18-90 years. A significant decrease in cortical width and area was seen (P =0.002 and <0.001 respectively), with no difference between sexes. Haversian canal density increased significantly with age by approximately 9% per decade (P = 0.032) but Haversian canal area tended to be lower, resulting in no overall age-related difference in cortical porosity. Haversian canal area was significantly higher in the endosteal section than in the periosteal section of the cortex (P = 0.019) but the Haversian canal density was lower, resulting in similar overall porosity in the two sections. In conclusion, our results demonstrate an age-related decrease in iliac crest cortical width in men and women and an increase in Haversian canal density, but no overall change in cortical porosity.


Assuntos
Envelhecimento/fisiologia , Densidade Óssea , Ílio/patologia , Ílio/fisiologia , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores Sexuais , Adulto Jovem
2.
Bone ; 44(4): 629-33, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19121416

RESUMO

INTRODUCTION: We have reported that after an acute stroke, intravenous zoledronate prevented bone loss in the hemiplegic hip. Participants from the trial also volunteered for trans-iliac bone biopsy, to assess the early effects of stroke and zoledronate on iliac bone remodelling. METHODS: Patients with acute stroke were randomly assigned to a single intravenous dose of zoledronate 4 mg or placebo within 5 weeks of stroke. Biopsies from 14 patients (3 female, 11 male, mean age 71+/-11) were suitable for analysis. These were taken at mean 10 weeks (+/-2) post-stroke, and included 5 patients who had received zoledronate. Histomorphometry was performed on undecalcified sections using light and fluorescence microscopy. Static and dynamic indices of remodelling were compared to a local reference range from healthy controls. Osteoclasts and their precursors were identified on frozen sections using tartrate resistant acid phosphatase (TRAP) staining. Dual-energy x-ray absorptiometry (DXA) of the proximal femora was performed at baseline and 6 months later. RESULTS: The eroded surface in cancellous bone (ES/BS) was significantly higher in stroke patients than controls (5.7% vs. ref 1.6%, p<0.0001). Although ES/BS did not differ between zoledronate and placebo-treated groups, there were significantly fewer osteoclasts and their precursors in zoledronate-treated individuals (p=0.023). Bone formation indices (osteoid surface, OS/BS and mineralising surface, MS/BS) were significantly lower in stroke patients than controls and although OS/BS was higher in the zoledronate group than the placebo group (p=0.033), MS/BS was not different (p=0.924). There were no differences between hemiplegic and unaffected sides for any histomorphometric parameter despite asymmetric reductions in hip bone mineral density (p=0.013). CONCLUSION: Stroke patients had higher resorption indices and lower bone forming surfaces than controls, consistent with uncoupling of bone remodelling. These findings are preliminary and a larger study is required to evaluate the contributions of gender, age and hemiplegic status to the remodelling imbalance. Zoledronate therapy was associated with a reduction in osteoclastic cell numbers consistent with its known mode of action in bone.


Assuntos
Conservadores da Densidade Óssea/uso terapêutico , Remodelação Óssea/efeitos dos fármacos , Difosfonatos/uso terapêutico , Ílio/efeitos dos fármacos , Imidazóis/uso terapêutico , Osteoporose/prevenção & controle , Acidente Vascular Cerebral/complicações , Absorciometria de Fóton , Idoso , Idoso de 80 Anos ou mais , Densidade Óssea/efeitos dos fármacos , Feminino , Hemiplegia/etiologia , Quadril , Humanos , Ílio/patologia , Masculino , Microscopia de Fluorescência , Pessoa de Meia-Idade , Osteoclastos/efeitos dos fármacos , Osteoporose/etiologia , Ácido Zoledrônico
3.
J Bone Miner Res ; 22(7): 1031-6, 2007 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-17501624

RESUMO

UNLABELLED: Use of activation frequency as a measure of remodeling rate assumes co-regulation of remodeling rate and remodeling balance. In iliac crest biopsy specimens from 57 healthy subjects 19-80 yr of age, no correlations were shown between these variables, an observation that challenges the use of activation frequency as an estimate of remodeling rate. INTRODUCTION: The histomorphometric derivation of activation frequency assumes that the remodeling rate is dependent on the duration of the remodeling cycle and the amount of bone formed in individual remodeling units. This implies that remodeling balance and remodeling rate are co-regulated. We tested this assumption in normal human adult cancellous bone. MATERIALS AND METHODS: Relationships between indices of bone formation at the basic multicellular unit (BMU) level (wall width and mineral apposition rate) and indices of remodeling rate (mineralizing perimeter and osteoid perimeter) were examined in iliac crest biopsies obtained from 57 healthy adults (24 men) 19-80 yr of age. RESULTS: Univariate analysis revealed a negative correlation between wall width and osteoid perimeter (r = -0.38; p = 0.0004), but there was no correlation between wall width and mineralizing perimeter or between mineral apposition rate and either mineralizing or osteoid perimeter. After adjustment for age and sex, the association between wall width and osteoid perimeter was no longer observed. Both wall width and mineral apposition rate correlated negatively with age (r = -0.75, p < 0.0001 and r = -0.27, p = 0.05, respectively). CONCLUSIONS: Our results indicate that remodeling balance and remodeling rate are not co-regulated in adult human bone. Activation frequency, as currently derived from histomorphometric variables, may therefore be unreliable as an indicator of remodeling rate.


Assuntos
Remodelação Óssea/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Calcificação Fisiológica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
4.
Bone ; 36(3): 562-7, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15777681

RESUMO

The beneficial skeletal effects of menopausal estrogen replacement therapy (HRT) are well documented. The role of secondary mineralization of bone as a determinant of bone quality is now well established in postmenopausal women treated with bisphosphonates or SERMs. The aim of present study was to investigate the effect of conventional and high doses of estrogen on the main parameters reflecting the degree of mineralization of bone (DMB). Bone biopsies were obtained from 20 women with osteopenia or osteoporosis before and after 24 months (18 to 38 months) of conventional HRT, and from 19 women who had received high doses of estradiol (implant 100 mg every 3-6 months for 1.5-20 years). DMB parameters (mean DMB, DMB Freq. Max. and Heterogeneity Index of the individual distributions of DMB) were measured using quantitative microradiography in cortical, cancellous, and total bone and expressed as g mineral/cm(3) bone. Values obtained in women before HRT were lower than those reported in pre- and postmenopausal control women. After conventional HRT, there was an increase in mean DMB (total bone) of 4.4 +/- 1.9% (mean +/- SEM) versus pre-treatment values (4.1 +/- 2.1% in cortical bone, 4.5 +/- 2.3% in cancellous bone); these differences did not reach statistical significance (P = 0.055). Results were similar for DMB Freq. Max. but Heterogeneity Index was not significantly changed. After high dose estradiol therapy, mean DMB (total bone) was 6.9 +/- 1.9% higher than in untreated women (8.6 +/- 2.1% in cortical bone, 6.5 +/- 2.1% in cancellous bone); this difference was statistically significant (P

Assuntos
Calcificação Fisiológica/efeitos dos fármacos , Terapia de Reposição de Estrogênios/métodos , Ílio/efeitos dos fármacos , Ílio/diagnóstico por imagem , Osteoporose Pós-Menopausa/diagnóstico por imagem , Osteoporose Pós-Menopausa/tratamento farmacológico , Idoso , Calcificação Fisiológica/fisiologia , Relação Dose-Resposta a Droga , Esquema de Medicação , Estrogênios/administração & dosagem , Feminino , Humanos , Microrradiografia/métodos , Pessoa de Meia-Idade
6.
Am J Respir Crit Care Med ; 166(11): 1470-4, 2002 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-12406824

RESUMO

This study reports the results of quantitative analysis of iliac bone histology in adults with cystic fibrosis (CF) and low bone mineral density (BMD). Twenty patients with CF had bone biopsies taken after double tetracycline labeling. Histomorphometric measurements were made by image analysis, and data were compared with those of healthy control subjects. Cancellous bone area was lower in the patients with CF (p = 0.003), and there was a trend towards a decrease in cancellous bone connectivity. Bone formation rate at tissue level was significantly lower in patients with CF (p = 0.0002). Wall width, representing the amount of bone formed within individual remodeling units, was decreased (p < 0.0001), as was mineralizing perimeter and mineral apposition rate. Analysis of resorption cavities revealed lower cavity area, reconstructed surface lengths, and cavity depths (p < 0.003) in patients with CF, whereas eroded surface area was higher (p = 0.0004). Our results demonstrate low cancellous bone volume in adult patients with CF with low BMD, the main cause of which appears to be low bone formation at tissue and cellular level. Osteomalacia was diagnosed in one patient. This condition should be excluded as a cause of low bone mineral density in patients with CF and vitamin D insufficiency corrected.


Assuntos
Fibrose Cística/patologia , Ílio/patologia , Adulto , Biópsia , Densidade Óssea , Remodelação Óssea , Fibrose Cística/fisiopatologia , Humanos , Valores de Referência
7.
Transpl Int ; 15(6): 290-5, 2002 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12072899

RESUMO

Osteoporosis is a common and serious complication of solid organ transplantation. Effective therapeutic regimens have not been established but evidence that increased bone turnover is responsible for bone loss early after transplantation provides a rationale for the use of anti-resorptive agents in the peri-operative period. We have examined the effects of a single pre-operative infusion of pamidronate, 60 mg, on bone remodelling and turnover in a prospective study of 12 patients, four male and eight female aged 19-61 years, with chronic liver disease, who formed a subgroup of a larger randomised controlled single-blind study. Iliac-crest biopsies were obtained before and 3 months after liver transplantation and histomorphometry performed using image analysis. In untreated patients ( n=5) a significant increase in bone formation rate at tissue level was demonstrated at 3 months in comparison to pre-operative values (0.035+/-0.013 vs. 0.161+/-0.12 microm(2)/microm/day; mean +/- SD, P=0.003). In patients treated with pamidronate ( n=7) no significant increase in bone formation rate was demonstrated at 3 months, although there was a trend towards an increase in indices of bone turnover. In this group there was also a significant reduction in erosion cavity length (210.4+/-63.8 vs. 179.8+/-67.5 microm; P=0.03) and non-significant reductions in other indices of erosion cavity size. These results indicate that pre-operative administration of pamidronate in patients with chronic liver disease prevents, at least in part, the increase in bone turnover which occurs in untreated patients after transplantation.


Assuntos
Remodelação Óssea/efeitos dos fármacos , Difosfonatos/uso terapêutico , Transplante de Fígado/efeitos adversos , Osteoporose/prevenção & controle , Adulto , Reabsorção Óssea/prevenção & controle , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pamidronato , Estudos Prospectivos , Método Simples-Cego
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...